Marko Jörg

Marko Jörg

Auto-generated profile, based on publicly available information

Marko Jörg

Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2026 in Molecular Psychiatry
Verified
Journal Article
Open access
MJMarko Jörg
Marko Jörg
LWLukas Walz
Lukas Walz
SNSebastian Nathal
Sebastian Nathal
MKMarco Kristen
Marco Kristen
CLChristine Lietz
Christine Lietz
KFKristina Friedland
Kristina Friedland
Alzheimer’s disease (AD) is a heterogeneous neurodegenerative disorder, highlighting the need to identify novel molecular regulators for effective treatment development. Angiogenin (ANG), a stress-responsive ribonuclease that inhibits apoptosis by generating 5′-tRNA fragments, is a candidate whose expression and regulation in AD is not understood. Here, we investigated ANG expression and regulation using AD cell and animal models, postmortem human brain tissue, and transcriptomic datasets ( n = 645). We found that ANG is dysregulated in AD in a sex-dependent manner, altering downstream levels of 5′-tiRNA Gly-GCC . Our analysis revealed female-specific molecular subtypes, absent in males: Subtype 1 featured low ANG levels with increased inflammation and neuronal death; subtype 2 exhibited higher ANG expression and intermediate pathology; subtype 3, marked by the highest ANG levels, showed reduced inflammation, slower cognitive decline, and extended survival. These findings position ANG as a key modulator of neuroinflammation and apoptosis in AD, highlighting its potential as a treatment strategy.

29 January 2026 in RNA
Verified
Journal Article
Closed access
MJMarko Joerg
Marko Joerg
MKMarco Kristen
Marco Kristen
LWLukas Walz
Lukas Walz
CLChristine Lietz
Christine Lietz
MMMax Mueller
Max Mueller
KFKristina Friedland
Kristina Friedland
TRNA-derived fragments have emerged as critical regulators in various biological processes, but reliable methods for their quantification remain a challenge due to their small size and extensive RNA modifications. In this study, we present the newly developed Complementary DNA Oligonucleotide Direct In-Gel Quantification (cDINGQ) method for tRF analysis and compare it with traditional radioactive [ 32 P] Northern blotting, non-radioactive approaches, and high-throughput Illumina sequencing under different experimental conditions. The cDINGQ method, utilizing Cy5-labeled hybridization probes, offers high specificity and sensitivity for detecting tRFs with significantly reduced processing time and costs. By applying these techniques to an Alzheimer’s disease (AD) cell model, we demonstrate the reliability of these methods in detecting subtle variations in tRF abundance. Our findings highlight the sensitivity, specificity, and applicability of each method, addressing limitations such as RNA input requirements and probe hybridization conditions. The study further explores the utility of these methods for detecting tRFs in various biological contexts, emphasizing their potential for future research and biomarker discovery in disease-related studies.

16 March 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
FCFelix Claussen
Felix Claussen
JBJohannes Andreas Blechar
Johannes Andreas Blechar
JAJozef Al-Gousous
Jozef Al-Gousous
DFDominik Albrecht Hugo Fuchs
Dominik Albrecht Hugo Fuchs
EKErik Kersten
Erik Kersten
Peter LangguthPeter Langguth
Peter Langguth
Enteric-coated dosage forms often suffer from sluggish post-gastric emptying drug release. This work focuses on developing novel enteric polymers as an approach to overcome this problem. The well-known polymer structures of Eudragit® L 100 and L 100-55 were esterified with the α-hydroxycarboxylic acids l-lactic, d,l-lactic and glycolic acid. A resulting partial positive charge arises within the ester linkage, reducing the pKa value of the polymer. This translates to more facile deprotonation of the carboxylic acid moieties, which enables more rapid polymer dissolution and consequently faster drug release. The dissolution pH threshold was reduced from pH 5.5 for the established Eudragit® L 100-55 to around 5, while the valuable acid-resistant properties of the polymethacrylates were preserved. Capsules filled with paracetamol were coated with the modified polymers as well as with the commercially available materials Eudragit® L 100 and L 100-55. In 0.01 M hydrochloric acid all coated capsules remained intact without any significant drug release. However, in 15 mM phosphate buffer (pH 6.5) the drug release from the formulations based on the novel polymers was significantly enhanced compared to formulations with Eudragit® L 100 and L 100-55. The increased release rate was connected to the faster dissolution of the modified polymers. This novel series of enteric polymers could help to overcome clinical problems associated with the currently used enteric polymers.

2 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MJMarko Joerg
Marko Joerg
LWLukas Walz
Lukas Walz
MLMarc Lander
Marc Lander
LBLarissa Bessler
Larissa Bessler
SNSebastian Nathal
Sebastian Nathal
KFKristina Friedland
Kristina Friedland
TRNA modifications are critical regulators of RNA stability, decoding fidelity, and cellular stress adaptation, yet their contribution to human neurodegenerative disease remains poorly understood. Beyond their established functions in translational control, emerging evidence shows that RNA modifications influence neurogenesis, neurodevelopment, neuronal function, brain-cell differentiation, and cellular plasticity. Consequently, dysregulation of these molecular processes is increasingly recognized as a mechanistic contributor to neurodegenerative disorders. Alzheimer’s disease (AD), characterized by amyloid pathology, synaptic dysfunction, and progressive neuronal loss, has recently been linked to disturbances in RNA metabolism, suggesting that alterations in the epitranscriptome may represent an underexplored dimension of AD pathophysiology. Here, we systematically profiled the tRNA epitranscriptome across cellular and animal models of AD, as well as in human postmortem brain tissue from non-demented controls and AD patients, using liquid chromatography-tandem mass spectrometry (LC-MS/MS). This method enables highly sensitive quantification of RNA modifications, with limits of detection in the low femtomole range. Across our models, we identified a conserved yet sex-specific remodeling of the tRNA modification landscape in AD. Because therapeutic options and early diagnostic tools for AD remain limited, we leveraged these findings to develop a tRNA-centered RNA-modification score that integrates both nucleobase-specific modification patterns and neuropathological disease severity into a quantitative metric. Together, our findings identify the tRNA epitranscriptome as a unifying molecular sex-specific signature of AD, linking disease pathology and sex to impaired RNA metabolism. This line of research opens a new path toward establishing early biomarkers or diagnostic tools for AD. Graphical

5 May 2026 in eLife
Verified
Journal Article
Open access
TBTamer Butto
Tamer Butto
SPStefan Pastore
Stefan Pastore
MMMax Müller
Max Müller
KIKaushik Viswanathan Iyer
Kaushik Viswanathan Iyer
MJMarko Jörg
Marko Jörg
SGSusanne Gerber
Susanne Gerber
Nanopore technology offers real-time sequencing opportunities, providing rapid access to sequenced data and allowing researchers to manage the sequencing process efficiently, resulting in cost-effective strategies. Here, we present focused case studies demonstrating the versatility of real-time transcriptomics analysis in rapid quality control for long-read RNA-seq. We illustrate its utility through four experimental setups: (1) transcriptome profiling of distinct human cellular populations, (2) identification of experimentally enriched transcripts, (3) transcriptional analysis of cells under heat shock conditions, and (4) identification of experimentally manipulated genes (knockout and overexpression) in several yeast strains. We show how to perform multiple layers of quality control as soon as sequencing has started, addressing both the quality of the experimental and sequencing traits. Real-time quality control measures assess sample/condition variability and determine the number of identified genes per sample/condition. Furthermore, real-time differential gene/transcript expression analysis can be conducted at various time points post-sequencing initiation (PSI), revealing dynamic changes in gene/transcript expression between two conditions. Using real-time analysis, which occurs in parallel to the sequencing run, we identified differentially expressed genes/transcripts as early as 1 hr PSI. These changes were consistently observed throughout the entire sequencing process. We discuss the new possibilities offered by real-time data analysis, which have the potential to serve as a valuable tool for rapid and cost-effective quality checks in specific experimental settings and can be potentially integrated into clinical applications in the future.